RT Journal Article
SR Electronic
T1 Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.05.26.445838
DO 10.1101/2021.05.26.445838
A1 Delphine Planas
A1 David Veyer
A1 Artem Baidaliuk
A1 Isabelle Staropoli
A1 Florence Guivel-Benhassine
A1 Maaran Michael Rajah
A1 Cyril Planchais
A1 Françoise Porrot
A1 Nicolas Robillard
A1 Julien Puech
A1 Matthieu Prot
A1 Floriane Gallais
A1 Pierre Gantner
A1 Aurélie Velay
A1 Julien Le Guen
A1 Najibi Kassis-Chikhani
A1 Dhiaeddine Edriss
A1 Laurent Belec
A1 Aymeric Seve
A1 Hélène Péré
A1 Laura Courtellemont
A1 Laurent Hocqueloux
A1 Samira Fafi-Kremer
A1 Thierry Prazuck
A1 Hugo Mouquet
A1 Timothée Bruel
A1 Etienne Simon-Lorière
A1 Felix A. Rey
A1 Olivier Schwartz
YR 2021
UL http://biorxiv.org/content/early/2021/05/27/2021.05.26.445838.abstract
AB The SARS-CoV-2 B.1.617 lineage emerged in October 2020 in India1–6. It has since then become dominant in some indian regions and further spread to many countries. The lineage includes three main subtypes (B1.617.1, B.1617.2 and B.1.617.3), which harbour diverse Spike mutations in the N-terminal domain (NTD) and the receptor binding domain (RBD) which may increase their immune evasion potential. B.1.617.2 is believed to spread faster than the other versions. Here, we isolated infectious B.1.617.2 from a traveller returning from India. We examined its sensitivity to monoclonal antibodies (mAbs) and to antibodies present in sera from COVID-19 convalescent individuals or vaccine recipients, in comparison to other viral lineages. B.1.617.2 was resistant to neutralization by some anti-NTD and anti-RBD mAbs, including Bamlanivimab, which were impaired in binding to the B.1.617.2 Spike. Sera from convalescent patients collected up to 12 months post symptoms and from Pfizer Comirnaty vaccine recipients were 3 to 6 fold less potent against B.1.617.2, relative to B.1.1.7. Sera from individuals having received one dose of AstraZeneca Vaxzevria barely inhibited B.1.617.2. Thus, B.1.617.2 spread is associated with an escape to antibodies targeting non-RBD and RBD Spike epitopes.Competing Interest StatementC.P., H.M., O.S, T.B., F.R. have a pending patent application for the anti-RBD mAbs described in the present study (PCT/FR2021/070522).